Business
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the
About this update from Boston Scientific Corporation
[{"type":"image","alt":"Elutia Inc.","displaySize":"","headline":null,"caption":"Elutia Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":67,"url":"https://media.zenfs.com/en/globenewswire.com/a29e66fb8a73dd1618af733c91ecea76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c1mHLTLmof012jV7WnpAyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a29e66fb8a73dd1618af733c91ecea76","width":300,"height":67}},"lazy":false},{"type":"text","content":"EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction","length":120,"tagName":"p"},{"type":"text","content":"Conference call today at 5:00 p.m. ET / 2:00 p.m. PT","length":52,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibiotic bioenvelope choice in cardiac implantable electronic device procedures, delivering robust revenue growth and expanding access through national group purchasing organization (GPO) contracts, value analysis committee (VAC) approvals, and a strategic distribution partnership with Boston Scientific. The Company also advanced its next-generation drug-eluting biomatrix pipeline, featuring the NXT-41 platform for breast reconstruction with initial product launch planned for the second half of 2026.","length":843,"tagName":"p"},{"type":"text","content":"Business Highlights:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"EluPro Momentum: Second quarter 2025 revenue up 49% sequentially. Total BioEnvelope revenue reached $3.5 million, up 33% year-over-year, with EluPro now contributing about two-thirds of total BioEnvelope sales.","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Robust Market Access of EluPro: VAC approvals now more than 160 centers, averaging about 12 new approvals monthly; customer base has grown more than 15x since launch.","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong Clinical Demand: EluPro customers are delivering meani...